BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 19, 2007
View Archived Issues
Recent Incyte patent reports novel agents for HIV infection
Read More
Novel agents for cardiovascular disorders disclosed in recent patents
Read More
RANKL: Target To Watch for development of therapeutics for treatment of osteolytic bone disorders
Read More
Biota and MedImmune begin RSV drug phase Ia clinical trials in adults
Read More
Patient enrollment on target for Avicena's phase III Parkinson's disease trial
Read More
Neuroprotective activity of olomoucine seen in status epilepticus model
Read More
Urigen completes reverse merger with Valentis
Read More
Aquinox describes development of SHIP inhibitor MN-100
Read More
Positive initial phase I findings for FLAP inhibitor AM-103
Read More
Dual CB1/CB2 agonist from Novartis has antihyperalgesic activity
Read More
Organon and Dyax partner in autoimmune diseases and cancer
Read More
Manufacturing agreement signed for GMP production of hGH-CTP
Read More
Centrix signs manufacturing and supply agreement with Cedar for Northyx
Read More
Recent patents disclose new therapeutic agents for anxiety, depression, etc.
Read More
NicOx/Merck & Co. drug candidate enters phase I trial triggering milestone payment
Read More
Series A financing at GlycoVaxyn
Read More
ImmuPharma's files IND for pivotal phase II/III trial for lupus
Read More
BioCryst and Roche to begin phase II study of BCX-4208 for psoriasis
Read More
Millennium begins phase III trial of Velcade for newly diagnosed MM
Read More
ProMetic BioSciences and Darier to codevelop PBI-1308
Read More
Amgen acquires Alantos Pharmaceuticals
Read More
Positive results for BioLineRx's study of first-in-class GABA-enhanced antipsychotic
Read More
Update on Hollis-Eden's phase I trial of HE-3286 for type 2 diabetes
Read More
Second approvable letter for eprodisate
Read More
Newest addition to Integrity's Disease Briefings collection sheds light on malaria
Read More
